FFO
UTHR icon

Fortitude Family Office’s United Therapeutics UTHR Stock Holding History

Fortitude Family Office’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.7K Buy
64
+21
+49% +$11.8K 0.01% 368
2026
Q1 		$25.5K Buy
43
+26
+153% +$12.9K 0.01% 376
2025
Q4 		$8.28K Hold
17
– – ﹤0.01% 644
2025
Q3 		$7.13K Buy
17
+1
+6% +$336 ﹤0.01% 685
2025
Q2 		$4.6K Buy
+16
New +$4.78K ﹤0.01% 816

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Fortitude Family Office's UTHR Position: Q2 2026 in Review

Fortitude Family Office increased its United Therapeutics (UTHR) stake by 49% in Q2 2026, buying an estimated $11.8K and bringing the position to 64 shares worth $34.7K. The position accounts for 0.01% of the portfolio, ranked #368.

Fortitude Family Office first reported a position in UTHR in Q2 2025 and has held it in 5 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Fortitude Family Office held 64 shares of United Therapeutics worth $34.7K as of Q2 2026.
  • Fortitude Family Office bought 21 United Therapeutics shares in Q2 2026, an estimated $11.8K.
  • United Therapeutics made up 0.01% of Fortitude Family Office's portfolio in Q2 2026, its #368 holding.
  • Fortitude Family Office first reported a position in United Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.